Naoki Yoshimura results 11
· Newest (Page 1/1, per page 25)
Author: Naoki Yoshimura ×Clear All Filters
Search Results
Background Obinutuzumab, a Type II anti-CD20 antibody, is used to treat follicular lymphoma. A major mode of action of obinutuzumab is antibody-dependent cellular cytotoxicity (ADCC). Knowledge of the mechanisms of resistance to obinutuzumab is important for the development of next-line strategies to follow obinutuzumab-containing therapy, including obinutuzumab retreatment. Unfortunately, the mechanisms by which tumor cells a...
Abstract of Poster PresentationNARA Subscribed
Previous1Next